Three Biotech Investment Ideas from Cormorant Asset Management
The biotech industry is regaining ground it lost in 2016 at full speed.
Hedge Fund - Cormorant Asset Management
Get Email AlertsBihua Chen Bio, Returns, AUM, Net Worth
Manager biography is currently missing.
Fund Profile
Filing Period:
| Fund Name: | Cormorant Asset Management |
| Manager | Bihua Chen |
| Portfolio Value | $1,785,149,209 |
| Change This QTR | +1175.64% |
Top 13F Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Security | Ticker | Shares | Value | Activity | % Port | History |
|---|---|---|---|---|---|---|---|
| 1. | Moonlake Immunotherapeutics | 8,142,100 | $415,247,100 | +19% | 23.26% | ||
| 2. | AMAM | 9,616,155 | $158,281,911 | +14% | 8.86% | ||
| 3. | APLS | 1,310,000 | $119,341,000 | -4% | 6.68% | ||
| 4. | BMEA | 3,570,872 | $78,380,646 | 4.39% | |||
| 5. | BBIO | 4,169,179 | $71,709,879 | -9% | 4.01% |
Latest 13D & 13G Filings
| Symbol | Company | Filed By | Filing Date | Filing |
|---|---|---|---|---|
| 2022-10-31 | ||||
| 2022-09-02 | ||||
| 2022-08-29 | ||||
| 2022-07-07 | ||||
| 2022-06-17 |
News, Interviews and Investor Letters
13G Filing: Cormorant Asset Management and Ignyta Inc. (RXDX)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing...
13G Filing: Cormorant Asset Management and Trillium Therapeutics Inc. (TRIL)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing...
Cormorant Asset Management's Bets on Alder Biopharmaceuticals Inc (ALDR) and Other Healthcare Stocks Show Strong Returns
Bihua Chen's Cormorant Asset Management is one of some 750 investors that we track and whose quarterly 13F filings we analyze to identify stocks that they are collectively bullish on.
Sunesis Pharmaceuticals Inc (SNSS): Cormorant Asset Management Reports New 5.14% Stake
Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) has a new shareholder in the form of Bihua Chen's Cormorant Asset Management.
Myokardia Inc (MYOK): Cormorant Asset Management Raises Its Stake
A recent 13G filing with the Securities and Exchange Commission revealed that Bihua Chen's Cormorant Asset Management has boosted its stake in Myokardia Inc (NASDAQ:MYOK) to 1.61 million shares, which...
Cormorant Asset Management Doesn't Think Corbus Pharmaceuticals Holdings Inc. (CRBP) Is Done Soaring Just Yet
In a new 13G filing with the SEC, Bihua Chen's Cormorant Asset Management reported owning 2.35 million shares of Corbus Pharmaceuticals Holdings Inc.
Gemphire Therapeutics Inc. (GEMP): Cormorant Asset Management Reports New Stake
According to a new 13G filing with the Securities and Exchange Commission, Bihua Chen's Cormorant Asset Management owns 900,000 shares of Gemphire Therapeutics Inc.
Clearside Biomedical Inc (CLSD): Cormorant Reveals 10.1% Stake
Bihua Chen's Cormorant Asset Management has revealed a position in Clearside Biomedical Inc (NASDAQ:CLSD), through a 13G filing issued with the SEC yesterday.
13G Filing: Cormorant Global Healthcare Master Fund and Proteostasis Therapeutics, Inc. (PTI)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing...
